690
Views
4
CrossRef citations to date
0
Altmetric
Original Articles

Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis

, , , , , , & show all
Pages 1411-1421 | Received 09 Sep 2020, Accepted 19 Dec 2020, Published online: 11 Jan 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Shanna Arnold Egloff, Xiting Cao, Rebecca Lachs, Casey Martin, Meredith Mattlin, Emma Fennell, Dillan Rayburn, Daniel Schlauch, Dax Kurbegov, Susan Ide & Minoo Battiwalla. (2023) Treatment patterns, resource utilization and clinical outcomes in patients with higher risk myelodysplastic syndromes (MDS) in United States community practices. Leukemia & Lymphoma 0:0, pages 1-12.
Read now

Articles from other publishers (3)

Vamsi Kota, Augustina Ogbonnaya, Eileen Farrelly, Bridgette Kanz Schroader, Aditya Raju, Fjoralba Kristo & Mehul Dalal. (2022) Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes. Future Oncology 18:36, pages 4017-4029.
Crossref
Wei Wang, Quanfang Luo, Qinpin Chen, Aiping Pang & Kuiyan Fang. (2022) Analysis of the Clinical Efficacy of Azacytidine + Venetoclax in the Treatment of Elderly Patients with Relapsed Refractory Acute Myeloid Leukemia. Evidence-Based Complementary and Alternative Medicine 2022, pages 1-4.
Crossref
Elizabeth A. Griffiths. (2021) Oral hypomethylating agents: beyond convenience in MDS. Hematology 2021:1, pages 439-447.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.